Prevention of tick-borne encephalitis by FSME-IMMUN vaccines: review of a clinical development programme.

Authors:
Address: Global R&D, Baxter BioScience, Wagramer Str. 17-19, A-1221 Vienna, Austria.
Journal:

Publication:

abstract

The need for highly effective tick-borne encephalitis (TBE) vaccines has increased globally due to a variety of factors including climate, social, economic and demographic changes, which are thought to have promoted the expansion of the endemic region of TBE viruses. The first TBE vaccine, FSME-IMMUN Inject, was introduced in the 1970s and has been continually improved since then to enhance both its safety and immunogenicity. The current formulation was established in 2001 and is marketed as FSME-IMMUN. This review summarizes findings of the clinical development programme since 2001 regarding determination of the optimal dose, conventional and rapid vaccination schedules, vaccination in adults, the elderly and special patient populations, safety, immunogenicity, and immunopersistence in adults and children, comparison of FSME-IMMUN with another commercially available TBE vaccine as well as post-marketing vaccination outcome. This successful research programme demonstrated the strong immunogenicity and continued safety of the FSME-IMMUN vaccine, which is further confirmed by the performance reported under field conditions.

Related Articles
Antibody response following administration of two paediatric tick-borne encephalitis vaccines using two different vaccination schedules.
Vaccine. 2009
Antibody response following administration of two paediatric tick-borne encephalitis vaccines using two different vaccination schedules.
Wittermann C, Schöndorf I, Gniel D. Vaccine. 2009 Mar 4; 27(10):1661-6. Epub 2008 Oct 20.
Randomized, phase II dose-finding studies of a modified tick-borne encephalitis vaccine: evaluation of safety and immunogenicity.
Vaccine. 2003
Randomized, phase II dose-finding studies of a modified tick-borne encephalitis vaccine: evaluation of safety and immunogenicity.
Ehrlich HJ, Pavlova BG, Fritsch S, Poellabauer EM, Loew-Baselli A, Obermann-Slupetzky O, Maritsch F, Cil I, Dorner F, Barrett PN. Vaccine. 2003 Dec 12; 22(2):217-23.
Safety and immunogenicity of the modified adult tick-borne encephalitis vaccine FSME-IMMUN: results of two large phase 3 clinical studies.
Vaccine. 2006
Safety and immunogenicity of the modified adult tick-borne encephalitis vaccine FSME-IMMUN: results of two large phase 3 clinical studies.
Loew-Baselli A, Konior R, Pavlova BG, Fritsch S, Poellabauer E, Maritsch F, Harmacek P, Krammer M, Barrett PN, Ehrlich HJ, et al. Vaccine. 2006 Jun 12; 24(24):5256-63. Epub 2006 Apr 3.
Review Advances in vaccination against tick-borne encephalitis.
Expert Rev Vaccines. 2008
Review Advances in vaccination against tick-borne encephalitis.
Rendi-Wagner P. Expert Rev Vaccines. 2008 Jul; 7(5):589-96.
Review Protection against tick-borne encephalitis with a new vaccine formulation free of protein-derived stabilizers.
J Travel Med. 2005
Review Protection against tick-borne encephalitis with a new vaccine formulation free of protein-derived stabilizers.
Zent O, Hennig R, Banzhoff A, Bröker M. J Travel Med. 2005 Mar-Apr; 12(2):85-93.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.